Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension safety study of filgotinib in ulcerative colitis
NL-OMON52973Phase 3Active, not recruiting
- Sponsor
- Galapagos NV
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of filgotinib in autoimmune colitis, sponsored by Galapagos NV. Primary endpoint: Long-term safety of filgotinib. Started Dec 2017; status: active, not recruiting.
02
Drugs
filgotinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON52973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52973.